PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Cash Return on Invested Capital (CROIC) 5 year CAGR for the quarter ending March 31, 2024

PureTech Health PLC Cash Return on Invested Capital (CROIC) 5 year CAGR is NA for the quarter ending March 31, 2024. The cash return on invested capital ratio measures the profitability of a company's invested capital based on its operating cash flow. It is calculated by dividing operating cash flow by the difference between total assets and current liabilities. This ratio indicates the company's ability to generate cash flow relative to the capital invested, excluding short-term liabilities. A higher ratio suggests more efficient cash flow generation from the invested capital. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

PureTech Health PLC Cash Return on Invested Capital (CROIC) for the quarter ending December 31, 2021 was -0.06, a -37.89% change year over year.
PureTech Health PLC Cash Return on Invested Capital (CROIC) for the quarter ending December 31, 2020 was -0.05, a -19.77% change year over year.
PureTech Health PLC Cash Return on Invested Capital (CROIC) for the quarter ending December 31, 2019 was -0.04.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends